Answers are grounded in this paper and cite their sources.
Demonstrates tissue-engineered myocardial patches using crosslinked submucosa and stem cells, indicating a customizable dual approach for congenital heart repair.
Congenital heart disease (CHD) is the leading cause of neonatal death worldwide. Tissue-engineered myocardial patches have emerged as a breakthrough solution with the potential to rebuild damaged myocardial tissue while providing essential paracrine signals for endogenous repair. In this study, a genipin-crosslinked small intestinal submucosa (GP-SIS) scaffold was prepared, which exhibits excellent mechanical properties and biocompatibility. Furthermore, two types of tissue-engineered myocardial patches based on GP-SIS scaffold combined with induced differentiation of umbilical cord mesenchymal stem cells (D-UC-MSCs) and urine-derived stem cells (D-USCs) was developed to address different clinical needs in the treatment of CHD. Both types of patches have good in vivo angiogenesis ability, among which GP-SIS/D-UC-MSCs are suitable for acute myocardial repair, while GP-SIS/D-USCs are more suitable for chronic treatment due to their non-invasive acquisition and personalized advantages. This dual strategy provides a new idea for the precise treatment of CHD.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: